User login
Key clinical point: Both types of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb), those against CGRP ligand (anti-CGRP) and those against CGRP receptor (anti-CGRP-R), showed benefits as preventive treatments for migraine; however, the proportion of anti-CGRP super responders was higher.
Major finding: Patients receiving anti-CGRP vs anti-CGRP-R had a significantly lower Migraine Disability Assessment scale score at 1 (P = .040) and 3 (P = .048) months and mean migraine days at 3 months (P = .01). The proportion of super responders were significantly higher in the anti-CGRP vs anti-CGRP-R group at 3-month (P = .041) and 6-month (P = .047) follow-ups.
Study details: This retrospective observational study included 152 patients with high-frequency episodic migraine or chronic migraine, of whom 68 were treated with anti-CGRP mAbs and 84 were treated with anti-CGRP-R mAbs.
Disclosures: This study did not receive any specific funding. Three authors declared serving as consultants and on scientific advisory boards or receiving speaker honoraria from various sources.
Source: Schiano di Cola F et al. An observational study on monoclonal antibodies against CGRP and its receptor. Eur J Neurol. 2023 (Mar 1). Doi: 10.1111/ene.15761
Key clinical point: Both types of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb), those against CGRP ligand (anti-CGRP) and those against CGRP receptor (anti-CGRP-R), showed benefits as preventive treatments for migraine; however, the proportion of anti-CGRP super responders was higher.
Major finding: Patients receiving anti-CGRP vs anti-CGRP-R had a significantly lower Migraine Disability Assessment scale score at 1 (P = .040) and 3 (P = .048) months and mean migraine days at 3 months (P = .01). The proportion of super responders were significantly higher in the anti-CGRP vs anti-CGRP-R group at 3-month (P = .041) and 6-month (P = .047) follow-ups.
Study details: This retrospective observational study included 152 patients with high-frequency episodic migraine or chronic migraine, of whom 68 were treated with anti-CGRP mAbs and 84 were treated with anti-CGRP-R mAbs.
Disclosures: This study did not receive any specific funding. Three authors declared serving as consultants and on scientific advisory boards or receiving speaker honoraria from various sources.
Source: Schiano di Cola F et al. An observational study on monoclonal antibodies against CGRP and its receptor. Eur J Neurol. 2023 (Mar 1). Doi: 10.1111/ene.15761
Key clinical point: Both types of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb), those against CGRP ligand (anti-CGRP) and those against CGRP receptor (anti-CGRP-R), showed benefits as preventive treatments for migraine; however, the proportion of anti-CGRP super responders was higher.
Major finding: Patients receiving anti-CGRP vs anti-CGRP-R had a significantly lower Migraine Disability Assessment scale score at 1 (P = .040) and 3 (P = .048) months and mean migraine days at 3 months (P = .01). The proportion of super responders were significantly higher in the anti-CGRP vs anti-CGRP-R group at 3-month (P = .041) and 6-month (P = .047) follow-ups.
Study details: This retrospective observational study included 152 patients with high-frequency episodic migraine or chronic migraine, of whom 68 were treated with anti-CGRP mAbs and 84 were treated with anti-CGRP-R mAbs.
Disclosures: This study did not receive any specific funding. Three authors declared serving as consultants and on scientific advisory boards or receiving speaker honoraria from various sources.
Source: Schiano di Cola F et al. An observational study on monoclonal antibodies against CGRP and its receptor. Eur J Neurol. 2023 (Mar 1). Doi: 10.1111/ene.15761